OncoMatch/Clinical Trials/NCT04636008
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Is NCT04636008 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Sintilimab for anti-pd-1 antibody.
Treatment: Sintilimab — This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CLINICAL T STAGE ≥T2 (clinical T stage)
clinical T stage ≥T2 on high-resolution pelvic magnetic resonance imaging (MRI)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any anti-rectal cancer treatment
Not received any anti-rectal cancer treatment previously
Cannot have received: blood, blood products and hematopoietic growth factor (e.g. granulocyte colony-stimulating factor)
Not received blood, blood products and hematopoietic growth factor (e.g. granulocyte colony-stimulating factor) within 2 weeks before inclusion
Lab requirements
Blood counts
hemoglobin ≥90 g/l, neutrophils ≥1500/mm3, platelets ≥75,000/mm3
Kidney function
creatinine ≤1.5 × uln, creatinine clearance ≥50 ml/min
Liver function
aspartate aminotransferase and alanine aminotransferase ≤3.0 × uln, bilirubin ≤1.5 × uln
Cardiac function
no obvious abnormality in electrocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify